A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

NCT04588298 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-negative Breast Cancer

Interventions

DRUG: AZD9833

Sponsor

AstraZeneca